Side effects of sodium valproate during long-term treatment in epilepsy. 1979

I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen

Side effects of sodium valproate during long-term treatment have been evaluated retrospectively in 55 patients suffering from refactory epilepsy. The side effects discovered in the study were slight and transient. In three of the 55 patients CNS side effects were noticed. Gastrointestinal symptoms were uncommon. One patient suffered from loss of hair which could have been attributed to sodium valproate. Severe side effects such as abnormal blood counts or organ damage were not discovered. The frequency of side effects was similar to those already reported in the literature except for gastrointestinal symptoms which were more infrequent than previously reported. No direct correlation could be established between the serum concentration of sodium valproate and the side effects.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000374 Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism. Aggressions
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
January 1983, Acta neurologica Scandinavica. Supplementum,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
January 1983, Acta neurologica Scandinavica. Supplementum,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
June 1977, British medical journal,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
March 1980, Neurology,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
March 1981, The Medical journal of Australia,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
March 1986, The Practitioner,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
June 1974, British medical journal,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
February 1988, Clinical endocrinology,
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
October 1977, Lancet (London, England),
I Ruuskanen, and H O Kilpeläinen, and P J Riekkinen
September 1976, Acta neurologica Scandinavica,
Copied contents to your clipboard!